New Role of Tumor Mutation Burden as a Predictor to Chemo/Targeted Therapy in Advanced Non-Small Cell Lung Cancer

培美曲塞 医学 肺癌 肿瘤科 内科学 队列 癌症 化疗 靶向治疗 顺铂
作者
Lin Chen,Xun Shi,Jun Zhao,Qiong He,Yang Shao,Xinmin Yu,Ying Jin
出处
期刊:Social Science Research Network [Social Science Electronic Publishing]
标识
DOI:10.2139/ssrn.3463249
摘要

Background: Accumulating evidence illustrates greater benefit of immunotherapy in tumors with high-TMB, whereas its impact on response to targeted therapy or chemotherapy is undefined.Methods: In this retrospective study, we investigated the correlation of tumor mutation burden (TMB) and progression-free survival (PFS) of NSCLC patients who received EGFR-TKIs or Pemetrexed/Platinum as first line therapy. TMB was evaluated by targeted next generation sequencing (tNGS). Patients were divided into low(L) / intermediate(I) / high(H) TMB groups by tertiles.Results: In EGFR-mutant cohort, TMB-L patients had an massively improved PFS compared to TMB-I/H patients(P=0.006) when treated with first generation of EGFR-TKIs. In EGFR/ALK wild-type cohort who received Pemetrexed/Platinum regimen, the ORR in TMB-L group was statistically superior than that of TMB-I/H groups (P=0.037), and patients with low TMB had a numerically, but not significantly prolonged PFS (P=0.22). No difference in PFS was observed between TMB-I and TMB-H groups in two treatment arms.Conclusions: Low nonsynonymous TMB indicated a favorable PFS for EGFR-TKIs and positive response to Pemetrexed/Platinum in certain cohorts with advanced NSCLC, which could potentially identify patients more suitable for targeted therapy or chemotherapy, rather than immunotherapy.Funding Statement: This work was supported by National Natural Science Foundation of China (Grant No.81702248) and Zhejiang medical and health science and technology project (Grant No.2018KY309).Declaration of Interests: The authors have declared no conflicts of interest.Ethics Approval Statement: Study protocols were approved by the Ethical Review Community of Zhejiang Cancer Hospital. The requirement of informed consent was waived by the committee as it was a retrospective research.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
妖孽宇完成签到,获得积分10
2秒前
简简单单完成签到,获得积分10
2秒前
550190946发布了新的文献求助10
2秒前
4秒前
111完成签到,获得积分10
4秒前
zhubin完成签到 ,获得积分10
4秒前
6秒前
田南松发布了新的文献求助10
9秒前
搬砖美少女完成签到,获得积分10
9秒前
nn发布了新的文献求助10
10秒前
7ohnny完成签到,获得积分10
11秒前
apckkk完成签到 ,获得积分10
13秒前
深情安青应助550190946采纳,获得10
14秒前
15秒前
16秒前
jbq完成签到 ,获得积分20
16秒前
YM完成签到,获得积分10
18秒前
生动柔发布了新的文献求助10
18秒前
大旭完成签到 ,获得积分10
19秒前
Fn完成签到 ,获得积分10
21秒前
zero完成签到,获得积分10
23秒前
瘦瘦谷兰完成签到,获得积分10
23秒前
zcz完成签到 ,获得积分10
24秒前
白嘉乐完成签到,获得积分10
25秒前
考研小白完成签到,获得积分10
25秒前
高妍纯完成签到 ,获得积分10
27秒前
29秒前
风中的丝袜完成签到,获得积分10
29秒前
赵赵完成签到,获得积分10
32秒前
32秒前
shiizii应助科研通管家采纳,获得10
33秒前
xuzj应助科研通管家采纳,获得10
33秒前
Mars应助科研通管家采纳,获得30
33秒前
Hello应助科研通管家采纳,获得10
33秒前
叶梓轩完成签到 ,获得积分10
33秒前
上官若男应助科研通管家采纳,获得10
33秒前
33秒前
33秒前
机智的锦程完成签到 ,获得积分10
34秒前
时尚俊驰发布了新的文献求助10
36秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022